Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | GOT1 | P17174 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL3661754 | 0.96 | ALDH1A1 (0.41) | MAPTGAAALDH1A1EDNRAGOT1 | |
| Bromide SCHEMBL3811129 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL11822056 | 0.76 | TDP1 (0.54) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL11833039 | 0.75 | GAA (0.41) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL31226082 | 0.75 | GAA (0.41) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL992666 | 0.75 | GAA (0.41) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL9907139 | 0.74 | GAA (0.39) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL2646767 | 0.74 | GAA (0.39) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL1189496 | 0.74 | GAA (0.39) | MAPTGAAALDH1A1GOT1KDM4E | |
| SCHEMBL11632340 | 0.72 | L3MBTL1 (0.46) | MAPTALDH1A1EDNRASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12312333-B2 | SK channel positive allosteric modulators | CHAPMAN UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119371426-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119350320-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20240132501-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117756800-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11866439-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-4578464-A | 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-03-25 | — | — | US | disclosed |
| EP-0029130-B1 | 3,6,7,8-SUBSTITUTED-S-TRIAZOLO(4,3-B)-PYRIDAZINES, THEIR PREPARATION AND COMPOSITIONS COMPRISING THEM | THE DOW CHEMICAL COMPANY (US) | 1985-12-04 | — | — | EP | disclosed |
| US-4526890-A | Respiratory system disorders | THE DOW CHEMICAL COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0029130-A1 | 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them | THE DOW CHEMICAL COMPANY (US) | 1981-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | MAPT 692/4885GAA 3450/4885ALDH1A1 1904/4885 |
| US-20240132501-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MAPT 662/4885GAA 2007/4885ALDH1A1 1953/4885 |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | MAPT 2009/4885GAA 1172/4885ALDH1A1 1320/4885 |
| US-11866439-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | MAPT 662/4885GAA 2007/4885ALDH1A1 1953/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | MAPT 2583/4885GAA 138/4885ALDH1A1 560/4885 |
| US-12312333-B2 | SK channel positive allosteric modulators | KCNN1, KCNN4, KCNN2 | MAPT 2936/4885GAA 2648/4885ALDH1A1 4418/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | MAPT 1512/4885GAA 255/4885ALDH1A1 447/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | MAPT 662/4885GAA 2007/4885ALDH1A1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.